Abstract:Background: Pantothenate kinase-associated neurodegeneration (PKAN) is a rare autosomal recessive genetic disorder of PANK2, which enables mitochondrial synthesis of coenzyme A. Its loss causes neurodegeneration with iron accumulation primarily in motor-related brain areas. Symptoms include dystonia, parkinsonism, and other disabilities. PKAN has been categorized as classic PKAN, with an age of onset ≤ 10 years, rapid progression, and early disability or death; and atypical PKAN, with later onset, slower progression, generally milder, and more diverse symptom manifestations. Available treatments are mostly palliative. Information on the lived experience of patients with PKAN and their caregivers or on community-level disease burden is limited. It is necessary to engage patients as partners to expand our understanding and improve clinical outcomes. This patient-oriented research study used multiple-choice and free-form question surveys distributed by patient organizations to collect information on the manifestations and disease burden of PKAN. It also assessed respondents' experiences and preferences with clinical research to inform future clinical trials. Results: The analysis included 166 surveys. Most respondents (87%) were parents of a patient with PKAN and 7% were patients, with 80% from Europe and North America. The study cohort included 85 patients with classic PKAN (mean ± SD age of onset 4.4 ± 2.79 years), 65 with atypical PKAN (13.8 ± 4.79 years), and 16 identified as "not sure". Respondents reported gait disturbances and dystonia most often in both groups, with 44% unable to walk. The classic PKAN group reported more speech, swallowing, and visual difficulties and more severe motor problems than the atypical PKAN group. Dystonia and speech/swallowing difficulties were reported as the most challenging symptoms. Most respondents reported using multiple medications, primarily anticonvulsants and antiparkinsonian drugs, and about half had participated in a clinical research study. Study participants reported the most difficulties with the physical exertion associated with imaging assessments and travel to assessment sites. Conclusions: The survey results support the dichotomy between classic and atypical PKAN that extends beyond the age of onset. Inclusion of patients as clinical research partners shows promise as a pathway to improving clinical trials and providing more efficacious PKAN therapies.

Novel compound heterozygous mutations in the PANK2 gene in a Chinese patient with atypical pantothenate kinase-associated neurodegeneration.

Novel Compound Heterozygous of PARKIN Causes Early-Onset Parkinson's Disease

Novel PANK2 Mutations in Patients With Pantothenate Kinase-Associated Neurodegeneration and the Genotype–Phenotype Correlation

Phenotypic and Genotypic Features of Twenty Children with Classic Pantothenate Kinase-Associated Neurodegeneration

Novel mutation of the PRRT2 gene in two cases of paroxysmal kinesigenic dyskinesia: Two case reports

Natural history and genotype-phenotype correlation of pantothenate kinase-associated neurodegeneration

Case Report: Novel Compound Heterozygous Variants in the PANK2 Gene in a Chinese Patient Diagnosed with ASD and ADHD

A Familial Late-Onset Hereditary Ataxia Mimicking Pontocerebellar Hypoplasia Caused by A Novel Tsen54 Mutation

[Genetic Study of a Parkinson's Disease Pedigree Caused by Compound Heterozygous Mutations in PARK2 Gene].

PRRT2 mutations in a cohort of Chinese families with paroxysmal kinesigenic dyskinesia and genotype-phenotype correlation reanalysis in literatures.

Four novel rare mutations of PLA2G6 in Chinese population with Parkinson's disease.

A heterozygous de novo PSEN1 mutation in a patient with early-onset parkinsonism

Novel compound heterozygous of PARKIN causes early-onset Parkinson’s disease

Concurrent PANK2 and OCA2 variants in a patient with retinal dystrophy, hypopigmented irides and neurodegeneration

The first Vietnamese patient who presented late onset of pantothenate kinase-associated neurodegeneration diagnosed by whole exome sequencing: A case report

Novel Missense Variant in the TMEM151A Gene Causing Paroxysmal Kinesigenic Dyskinesia: a Case Report with Literature Review

Patient and caregiver experiences with pantothenate kinase-associated neurodegeneration (PKAN): results from a patient community survey

A Novel Homozygous SYNJ1 Mutation in Two Siblings with Typical Parkinson's Disease.

Mutation analysis of<i>Parkin</i>,<i>PINK1</i>,<i>DJ-1</i>and<i>ATP13A2</i>genes in Chinese patients with autosomal recessive early-onset Parkinsonism

Early-onset parkinsonism linked to combined heterozygous mutations in PANK2 and PLA2G6: A case report

Familial Paroxysmal Kinesigenic Dyskinesia is Associated with Mutations in the KCNA1 Gene